Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs.

In the last decades, inflammation has been recognized as being closely connected to cancer, and joint strategies encompassing chemotherapeutic and anti-inflammatory agents have been extensively studied. In this work, a series of novel cisplatin and oxaliplatin-based Pt(IV) complexes comprising non-steroidal anti-inflammatory drugs (NSAIDs) and their carboxyl ester analogues as axial moieties were synthesized. Several of the cisplatin-based Pt(IV) complexes 22-30 showed increased cytotoxicity in the human cancer cell lines CH1/PA-1, SW480 and A549 compared to the Pt(II) drug. For the most potent complex 26, comprising two aceclofenac (AFC) moieties, the formation of Pt(II)-9-methylguanine (9-MeG) adducts after activation with ascorbic acid (AsA) was proven. Additionally, a significant inhibition of cyclooxygenase (COX) activity and prostaglandin E2 (PGE2) production was observed, as well as increased cellular accumulation, depolarization of mitochondrial membranes, and strong proapoptotic potencies in SW480 cells. Overall, these systematic effects shown in vitro confer 26 as a potential anticancer agent combined with anti-inflammatory properties.

Forty Years after the Discovery of Its Nucleolytic Activity: [Cu(phen)2 ]2+ Shows Unattended DNA Cleavage Activity upon Fluorination.

[Cu(phen)2 ]2+ (phen=1,10-phenanthroline) is the first and still one of the most efficient artificial nucleases. In general, when the phen ligand is modified, the nucleolytic activity of its CuII complex is significantly reduced. This is most likely due to higher steric bulk of such ligands and thus lower affinity to DNA. CuII complexes with phen ligands having fluorinated substituents (F, CF3 , SF5 , SCF3 ) surprisingly showed excellent DNA cleavage activity-in contrast to the unsubstituted [Cu(phen)2 ]2+ -in the absence of the otherwise required classical, bioabundant external reducing agents like thiols or ascorbate. This nucleolytic activity correlates well with the half-wave potentials E1/2 of the complexes. Cancer cell studies show cytotoxic effects of all complexes with fluorinated ligands in the low µm range, whereas they were less toxic towards healthy cells (fibroblasts).

Making the SF5 Group More Accessible: A Gas-Reagent-Free Approach to Aryl Tetrafluoro-λ6 -sulfanyl Chlorides.

Modern pentafluorosulfanyl (SF5 ) chemistry has an Achilles heel: synthetic accessibility. Herein, we present the first approach to aryl-SF4 Cl compounds (key intermediates in state-of-the-art aryl-SF5 synthesis) that overcomes the reliance on hazardous fluorinating reagents and/or gas reagents (e.g. Cl2 ) by employing easy-to-handle trichloroisocyanuric acid, potassium fluoride, and catalytic amounts of acid. These simple, mild conditions allow direct access to aryl-SF4 Cl intermediates that either have not been or cannot be demonstrated using previous methods. Furthermore, the same approach provides access to aryl-SF3 and aryl-SeF3 compounds, which extend the applications of this chemistry beyond arene SF5 -functionalization, and demonstrate its ability to address a more general oxidative fluorination problem.

A Structurally Characterized Organometallic Plutonium(IV) Complex.

The blood-red plutonocene complex Pu(1,3-COT'')(1,4-COT'') (4; COT''=η8 -bis(trimethylsilyl)cyclooctatetraenyl) has been synthesized by oxidation of the anionic sandwich complex Li[Pu(1,4-COT'')2 ] (3) with anhydrous cobalt(II) chloride. The first crystal structure determination of an organoplutonium(IV) complex revealed an asymmetric sandwich structure for 4 where one COT'' ring is 1,3-substituted while the other retains the original 1,4-substitution pattern. The electronic structure of 4 has been elucidated by a computational study, revealing a probable cause for the unexpected silyl group migration.